Ori-C101 Demonstrates Remarkable Efficacy in Late-Stage Hepatocellular Carcinoma with Breakthrough Clinical Data

Source: Securities Daily

Newspaper Report (Reporter Zhang Wenxiang, Trainee Reporter Zhan Jianyu) On June 1, Oricell Therapeutics Holdings Limited

Qrigincell Therapeutics (hereinafter referred to as “Qrigincell”) announced that its independently developed GPC3-targeted CAR-T cell therapy product (Ori-C101) demonstrated superior anti-tumor activity and a manageable safety profile in the registrational Phase Ib (BEACON) trial involving patients with late-stage, heavily pretreated hepatocellular carcinoma (HCC) who had failed second-line therapy. The relevant data were selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The company stated that as of April 3, 2026, Ori-C101 demonstrated breakthrough efficacy in the registrational Phase I clinical trial (BEACON study): among 18 efficacy-evaluable subjects, it showed significant overall anti-tumor activity, with an objective response rate (ORR) of 50%. Notably, in the recommended Phase 2 dose (RP2D) cohort, the efficacy was further highlighted, with an ORR of up to 66.7% and a disease control rate (DCR) approaching 90%, significantly superior to existing second-line standard therapies.

According to the company, clinical observations have revealed that Ori-C101 not only has a rapid onset of action but also induces durable responses, with the vast majority of patients achieving remission at the first assessment. Notably, a case of deep remission was observed in this study: the patient achieved partial remission (PR) at the initial assessment, progressed to complete remission (CR) by the fourth month, and has maintained remission for 24 months, continuing to derive clinical benefit. Furthermore, Ori-C101 demonstrated an excellent safety profile, with no occurrences of neurotoxicity (ICANS) or off-target toxicity, and all cases of cytokine release syndrome (CRS) were within a manageable range.

(Edited by Wu Yue and Wang Shijun)